HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

BACKGROUND. HER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HER2 blockade. Preclinical findings show that it also might impair response to anti‐epidermal growth factor receptor (EGFR) treatmen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Sartore‐Bianchi, Andrea, Amatu, Alessio, Porcu, Luca, Ghezzi, Silvia, Lonardi, Sara, Leone, Francesco, Bergamo, Francesca, Fenocchio, Elisabetta, Martinelli, Erika, Borelli, Beatrice, Tosi, Federica, Racca, Patrizia, Valtorta, Emanuele, Bonoldi, Emanuela, Martino, Cosimo, Vaghi, Caterina, Marrapese, Giovanna, Ciardiello, Fortunato, Zagonel, Vittorina, Bardelli, Alberto, Trusolino, Livio, Torri, Valter, Marsoni, Silvia, Siena, Salvatore
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795149/
https://ncbi.nlm.nih.gov/pubmed/30952821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0785
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados